All In Biotech

Drug Trial Radar · NCT04316442

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Last checked: Nov 19, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Sep 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Sorrento Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The STI-6129-001 study is a three-stage, multicenter, open-label, dose-finding, phase 1b/2a trial. It is designed primarily to identify the recommended phase 2 dose (RP2D) of STI-6129 by assessing the safety, preliminary efficacy and pharmacokinetics of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of relapsed or refractory systemic AL amyloidosis. The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis patients who have received prior lines of treatment.

Conditions

  • Light Chain (AL) Amyloidosis

Interventions

  • STI-6129Biological

    Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of STI-6129 in AL amyloidosis patientsTime frame: Baseline through study completion at up to 14 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute Wertz Clinic

    Detroit, Michigan · Recruiting

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.